Results 151 to 160 of about 111,529 (192)
Hypercholesterolemia and LDL Apheresis
The International Journal of Artificial Organs, 2005 Several trials have assessed the link between low-density lipoprotein cholesterol (LDL) and the development of coronary heart disease (CHD). LDL apheresis provides an effective role in treating patients with familial hypercholesterolemia (FH) and in preventing the progression of coronary artery disease (CAD).
F. Morelli +6 more
openaire +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Transfusion and Apheresis Science, 2017
LDL apheresis has been developed as the treatment for refractory familial hypercholesterolemia (FH). Currently, plasma exchange, double membrane filtration, and selective LDL adsorption are available in Japan, and selective LDL adsorption is most common method. LDL apheresis can prevent atherosclerosis progression even in homozygous (HoFH). However, in
Hisashi, Makino +2 more
openaire +2 more sources
LDL apheresis has been developed as the treatment for refractory familial hypercholesterolemia (FH). Currently, plasma exchange, double membrane filtration, and selective LDL adsorption are available in Japan, and selective LDL adsorption is most common method. LDL apheresis can prevent atherosclerosis progression even in homozygous (HoFH). However, in
Hisashi, Makino +2 more
openaire +2 more sources
Immunosorbents for LDL-Apheresis
Biomaterials, Artificial Cells and Artificial Organs, 1990Low density lipoprotein (LDL) (1,03-1,05 g/ml) was utilized as antigen to obtain polyclonal (PcAb) and monoclonal (McAb) antibodies. Immunosorbents capable of selective removing LDL from human plasma were developed on the basis of the antibodies preparation.
S N, Pokrovsky +2 more
openaire +2 more sources
Atherosclerosis, 2003
Low density lipoprotein (LDL) apheresis provides a safe and effective means of treating patients with homozygous familial hypercholesterolaemia (FH). It also has a role in preventing the progression of coronary artery disease in heterozygotes and others with severe dyslipidaemia who are refractory to or intolerant of high doses of lipid-lowering drugs.
openaire +2 more sources
Low density lipoprotein (LDL) apheresis provides a safe and effective means of treating patients with homozygous familial hypercholesterolaemia (FH). It also has a role in preventing the progression of coronary artery disease in heterozygotes and others with severe dyslipidaemia who are refractory to or intolerant of high doses of lipid-lowering drugs.
openaire +2 more sources
Transfusion and Apheresis Science, 2007
LDL apheresis is a technology used worldwide for the treatment of refractory familial hypercholesterolemia [1]. In Italy, this extracorporeal treatment has been applied for the last 20 years, firstly by using plasma exchange and cascade filtration and by the end of the 1980’s introducing the first selective systems for LDL apheresis on a routine basis.
openaire +2 more sources
LDL apheresis is a technology used worldwide for the treatment of refractory familial hypercholesterolemia [1]. In Italy, this extracorporeal treatment has been applied for the last 20 years, firstly by using plasma exchange and cascade filtration and by the end of the 1980’s introducing the first selective systems for LDL apheresis on a routine basis.
openaire +2 more sources
Pleiotropic effects of LDL apheresis
Atherosclerosis Supplements, 2009LDL apheresis (LA), a technique employed to remove atherogenic lipoproteins, has been shown to exert a protective function on the vessel walls. This effect can be attributed to pleiotropic mechanisms that safeguard against endothelial dysfunction by reducing the concentrations of pro-inflammatory and pro-coagulation markers.
Alfonso, Ramunni +3 more
openaire +2 more sources
Current Treatment Options in Cardiovascular Medicine, 2006
Low-density lipoprotein (LDL)-apheresis is an effective means for acutely lowering plasma cholesterol (LDL reduction > 60%) and reducing cardiovascular events in patients with uncontrolled hypercholesterolemia who are genetically predisposed or resistant to standard therapy.
openaire +2 more sources
Low-density lipoprotein (LDL)-apheresis is an effective means for acutely lowering plasma cholesterol (LDL reduction > 60%) and reducing cardiovascular events in patients with uncontrolled hypercholesterolemia who are genetically predisposed or resistant to standard therapy.
openaire +2 more sources
What’s going on in LDL apheresis
Transfusion and Apheresis Science, 2007(1) immunoadsorption (IMA), which consists of selective removal of LDL from plasma using polyclonal sheep anti-LDL antibodies; (2) direct adsorption of lipoprotein from whole blood, hemoperfusion using non-hemolytic polyacrylate-coated polyacrilamide gel (DALI), with the advantage of a shorter procedure time; (3) presently available, a new system of ...
Daniela, Onofrillo, Patrizia, Accorsi
openaire +2 more sources
Release of microparticles in LDL apheresis
Transfusion and Apheresis Science, 2001Particle contamination of blood always takes place in extracorporeal systems and few studies have been conducted to evaluate potential risks. Particle concentration was measured in the efferent blood line on original equipment for two established LDL elimination procedures (DALI) (Fresenius) and Liposorber (Kaneka).
G B, Matic +5 more
openaire +2 more sources
Ldl-Apheresis on Affine Haemosorbents
Biomaterials, Artificial Cells and Artificial Organs, 1990There were synthesized new hemosorbents for selective removal of LDL, based on macroporous silica, immobilised by heparine (sorbent 1) and chytozane-sulphate (sorbent 2). Experimental data showed satisfactory hemo- and biocompatibility of the new sorbents. No significant alterations in biochemical parameters were observed.
, Lopukhin YuM +4 more
openaire +2 more sources